Ixekizumab - Eli Lilly

Drug Profile

Ixekizumab - Eli Lilly

Alternative Names: Anti-IL-17 MAb; Anti-IL-17 monoclonal antibody; IL-17 Ab; IL-17 antibody; Interleukin 17 antibody; LY-2439821; Taltz

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Class Antibodies; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action IL17A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Plaque psoriasis
  • Registered Erythrodermic psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Phase III Ankylosing spondylitis; Spondylarthritis
  • Phase II Bullous pemphigoid; Rheumatoid arthritis

Most Recent Events

  • 26 Sep 2017 Launched for Plaque psoriasis in Australia (SC) before September 2017
  • 11 Sep 2017 Preregistration for Psoriatic arthritis in European Union before September 2017 (SC)
  • 15 Aug 2017 Phase-II clinical trials in Bullous pemphigoid in USA (SC) (NCT03099538)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top